Medifast, Inc. Logo

Medifast, Inc.

MED

(2.5)
Stock Price

18,14 USD

9.99% ROA

14.47% ROE

6.88x PER

Market Cap.

201.904.404,00 USD

9.3% DER

0% Yield

3.81% NPM

Medifast, Inc. Stock Analysis

Medifast, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Medifast, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (80.31%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (13%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

5 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

6 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (773) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.9x) suggests it's overvalued, potentially making it an expensive investment.

8 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

10 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

11 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Medifast, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Medifast, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Medifast, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Medifast, Inc. Revenue
Year Revenue Growth
1996 16.504.000
1997 14.361.000 -14.92%
1998 15.901.000 9.68%
1999 4.651.000 -241.88%
2000 3.898.000 -19.32%
2001 5.022.000 22.38%
2002 12.345.000 59.32%
2003 25.379.000 51.36%
2004 27.340.000 7.17%
2005 40.129.000 31.87%
2006 74.086.000 45.83%
2007 83.779.000 11.57%
2008 105.445.000 20.55%
2009 165.618.000 36.33%
2010 257.552 -64204.68%
2011 298.189.000 99.91%
2012 356.706.000 16.4%
2013 356.886.000 0.05%
2014 285.285.000 -25.1%
2015 272.773.000 -4.59%
2016 274.534.000 0.64%
2017 301.563.000 8.96%
2018 501.003.000 39.81%
2019 713.672.000 29.8%
2020 934.842.000 23.66%
2021 1.526.087.000 38.74%
2022 1.598.577.000 4.53%
2023 943.476.000 -69.43%
2023 1.072.054.000 11.99%
2024 674.232.000 -59%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Medifast, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 1.300.000 100%
2015 1.800.000 27.78%
2016 2.000.000 10%
2017 1.500.000 -33.33%
2018 2.200.000 31.82%
2019 2.700.000 18.52%
2020 2.800.000 3.57%
2021 4.400.000 36.36%
2022 4.500.000 2.22%
2023 0 0%
2023 4.600.000 100%
2024 4.400.000 -4.55%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Medifast, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 217.573.000 100%
2013 0 0%
2014 161.961.000 100%
2015 157.331.000 -2.94%
2016 169.405.000 7.13%
2017 0 0%
2018 304.836.000 100%
2019 440.519.000 30.8%
2020 559.256.000 21.23%
2021 909.756.000 38.53%
2022 953.908.000 4.63%
2023 0 0%
2023 646.048.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Medifast, Inc. EBITDA
Year EBITDA Growth
1996 1.081.000
1997 -2.283.000 147.35%
1998 -512.000 -345.9%
1999 -2.172.000 76.43%
2000 671.000 423.7%
2001 895.000 25.03%
2002 2.026.000 55.82%
2003 4.165.000 51.36%
2004 4.321.000 3.61%
2005 5.800.000 25.5%
2006 10.555.000 45.05%
2007 9.076.000 -16.3%
2008 12.905.000 29.67%
2009 19.449.000 33.65%
2010 32.025 -60630.68%
2011 36.147.000 99.91%
2012 23.262.000 -55.39%
2013 44.972.000 48.27%
2014 30.246.000 -48.69%
2015 28.684.000 -5.45%
2016 26.859.000 -6.79%
2017 39.632.000 32.23%
2018 69.063.000 42.61%
2019 91.039.000 24.14%
2020 134.159.000 32.14%
2021 223.053.000 39.85%
2022 195.786.000 -13.93%
2023 115.684.000 -69.24%
2023 139.509.000 17.08%
2024 -19.236.000 825.25%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Medifast, Inc. Gross Profit
Year Gross Profit Growth
1996 7.288.000
1997 4.691.000 -55.36%
1998 5.804.000 19.18%
1999 2.346.000 -147.4%
2000 2.174.000 -7.91%
2001 2.811.000 22.66%
2002 8.658.000 67.53%
2003 18.554.000 53.34%
2004 20.594.000 9.91%
2005 29.968.000 31.28%
2006 55.849.000 46.34%
2007 62.315.000 10.38%
2008 80.113.000 22.22%
2009 125.325.000 36.08%
2010 192.469 -65014.38%
2011 224.496.000 99.91%
2012 268.035.000 16.24%
2013 267.846.000 -0.07%
2014 209.207.000 -28.03%
2015 201.315.000 -3.92%
2016 205.664.000 2.11%
2017 227.812.000 9.72%
2018 379.899.000 40.03%
2019 536.858.000 29.24%
2020 697.815.000 23.07%
2021 1.127.597.000 38.11%
2022 1.140.414.000 1.12%
2023 709.508.000 -60.73%
2023 775.850.000 8.55%
2024 493.752.000 -57.13%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Medifast, Inc. Net Profit
Year Net Profit Growth
1996 320.000
1997 -3.697.000 108.66%
1998 -949.000 -289.57%
1999 -3.192.000 70.27%
2000 1.303.000 344.97%
2001 588.000 -121.6%
2002 2.623.000 77.58%
2003 2.410.000 -8.84%
2004 1.747.000 -37.95%
2005 2.727.000 35.94%
2006 5.082.000 46.34%
2007 3.837.000 -32.45%
2008 5.435.000 29.4%
2009 11.963.000 54.57%
2010 19.611 -60901.48%
2011 18.541.000 99.89%
2012 15.876.000 -16.79%
2013 23.969.000 33.76%
2014 13.181.000 -81.85%
2015 20.058.000 34.29%
2016 17.835.000 -12.46%
2017 27.721.000 35.66%
2018 55.789.000 50.31%
2019 77.916.000 28.4%
2020 102.859.000 24.25%
2021 164.031.000 37.29%
2022 143.568.000 -14.25%
2023 92.524.000 -55.17%
2023 99.415.000 6.93%
2024 -32.616.000 404.8%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Medifast, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 0
1997 -1 0%
1998 0 0%
1999 -1 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 1 0%
2010 1 100%
2011 1 0%
2012 1 0%
2013 2 0%
2014 1 0%
2015 2 0%
2016 2 0%
2017 2 50%
2018 5 50%
2019 7 33.33%
2020 9 25%
2021 14 42.86%
2022 13 -16.67%
2023 8 -50%
2023 9 11.11%
2024 -3 400%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Medifast, Inc. Free Cashflow
Year Free Cashflow Growth
1996 -494.000
1997 -2.058.000 76%
1998 -2.239.000 8.08%
1999 -176.000 -1172.16%
2000 -145.000 -21.38%
2001 605.000 123.97%
2002 -1.521.000 139.78%
2003 -1.585.000 4.04%
2004 341.000 564.81%
2005 1.541.000 77.87%
2006 -2.139.000 172.04%
2007 -11.000 -19345.45%
2008 -1.946.000 99.43%
2009 14.960.000 113.01%
2010 16.714.000 10.49%
2011 20.210.000 17.3%
2012 28.881.000 30.02%
2013 30.754.000 6.09%
2014 18.512.000 -66.13%
2015 26.592.000 30.39%
2016 22.474.000 -18.32%
2017 39.995.000 43.81%
2018 55.876.000 28.42%
2019 74.203.000 24.7%
2020 139.309.000 46.73%
2021 60.336.000 -130.89%
2022 177.889.000 66.08%
2023 141.174.000 -26.01%
2023 28.252.000 -399.7%
2024 11.131.000 -153.81%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Medifast, Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 -220.000
1997 -1.903.000 88.44%
1998 -2.026.000 6.07%
1999 -148.000 -1268.92%
2000 -22.000 -572.73%
2001 651.000 103.38%
2002 2.456.000 73.49%
2003 1.748.000 -40.5%
2004 2.332.000 25.04%
2005 3.213.000 27.42%
2006 5.845.000 45.03%
2007 7.954.000 26.51%
2008 5.496.000 -44.72%
2009 20.313.000 72.94%
2010 28.769.000 29.39%
2011 34.870.000 17.5%
2012 40.264.000 13.4%
2013 42.360.000 4.95%
2014 25.536.000 -65.88%
2015 29.411.000 13.18%
2016 25.350.000 -16.02%
2017 43.237.000 41.37%
2018 60.816.000 28.91%
2019 84.261.000 27.82%
2020 145.196.000 41.97%
2021 94.545.000 -53.57%
2022 194.570.000 51.41%
2023 147.657.000 -31.77%
2023 29.930.000 -393.34%
2024 13.069.000 -129.02%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Medifast, Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 274.000
1997 155.000 -76.77%
1998 213.000 27.23%
1999 28.000 -660.71%
2000 123.000 77.24%
2001 46.000 -167.39%
2002 3.977.000 98.84%
2003 3.333.000 -19.32%
2004 1.991.000 -67.4%
2005 1.672.000 -19.08%
2006 7.984.000 79.06%
2007 7.965.000 -0.24%
2008 7.442.000 -7.03%
2009 5.353.000 -39.02%
2010 12.055.000 55.6%
2011 14.660.000 17.77%
2012 11.383.000 -28.79%
2013 11.606.000 1.92%
2014 7.024.000 -65.23%
2015 2.819.000 -149.17%
2016 2.876.000 1.98%
2017 3.242.000 11.29%
2018 4.940.000 34.37%
2019 10.058.000 50.88%
2020 5.887.000 -70.85%
2021 34.209.000 82.79%
2022 16.681.000 -105.08%
2023 6.483.000 -157.3%
2023 1.678.000 -286.35%
2024 1.938.000 13.42%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Medifast, Inc. Equity
Year Equity Growth
1996 5.574.000
1997 2.016.000 -176.49%
1998 2.147.000 6.1%
1999 -213.000 1107.98%
2000 1.210.000 117.6%
2001 2.538.000 52.32%
2002 5.578.000 54.5%
2003 17.077.000 67.34%
2004 19.206.000 11.09%
2005 22.021.000 12.78%
2006 28.166.000 21.82%
2007 32.420.000 13.12%
2008 38.173.000 15.07%
2009 52.932.000 27.88%
2010 71.956.000 26.44%
2011 73.402.000 1.97%
2012 90.786.000 19.15%
2013 98.416.000 7.75%
2014 80.476.000 -22.29%
2015 88.584.000 9.15%
2016 96.016.000 7.74%
2017 108.581.000 11.57%
2018 109.106.000 0.48%
2019 104.832.000 -4.08%
2020 157.246.000 33.33%
2021 202.474.000 22.34%
2022 155.044.000 -30.59%
2023 193.035.000 19.68%
2023 201.481.000 4.19%
2024 205.283.000 1.85%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Medifast, Inc. Assets
Year Assets Growth
1996 11.451.000
1997 6.944.000 -64.9%
1998 10.340.000 32.84%
1999 2.112.000 -389.58%
2000 3.125.000 32.42%
2001 3.357.000 6.91%
2002 9.888.000 66.05%
2003 24.232.000 59.19%
2004 25.968.000 6.69%
2005 30.545.000 14.98%
2006 36.927.000 17.28%
2007 43.724.000 15.55%
2008 51.037.000 14.33%
2009 64.140.000 20.43%
2010 94.059.000 31.81%
2011 105.665.000 10.98%
2012 130.251.000 18.88%
2013 132.650.000 1.81%
2014 115.910.000 -14.44%
2015 117.326.000 1.21%
2016 121.216.000 3.21%
2017 145.929.000 16.93%
2018 169.429.000 13.87%
2019 194.653.000 12.96%
2020 276.084.000 29.5%
2021 398.326.000 30.69%
2022 316.213.000 -25.97%
2023 320.019.000 1.19%
2023 309.908.000 -3.26%
2024 293.531.000 -5.58%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Medifast, Inc. Liabilities
Year Liabilities Growth
1996 5.877.000
1997 4.928.000 -19.26%
1998 8.193.000 39.85%
1999 2.325.000 -252.39%
2000 1.915.000 -21.41%
2001 819.000 -133.82%
2002 4.310.000 81%
2003 7.155.000 39.76%
2004 6.762.000 -5.81%
2005 8.524.000 20.67%
2006 8.761.000 2.71%
2007 11.304.000 22.5%
2008 12.864.000 12.13%
2009 11.208.000 -14.78%
2010 22.103.000 49.29%
2011 32.263.000 31.49%
2012 39.465.000 18.25%
2013 34.234.000 -15.28%
2014 35.434.000 3.39%
2015 28.742.000 -23.28%
2016 25.200.000 -14.06%
2017 37.348.000 32.53%
2018 60.323.000 38.09%
2019 89.821.000 32.84%
2020 118.838.000 24.42%
2021 195.852.000 39.32%
2022 161.169.000 -21.52%
2023 126.984.000 -26.92%
2023 108.427.000 -17.11%
2024 88.248.000 -22.87%

Medifast, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
70.42
Net Income per Share
2.68
Price to Earning Ratio
6.88x
Price To Sales Ratio
0.26x
POCF Ratio
3.32
PFCF Ratio
3.71
Price to Book Ratio
0.98
EV to Sales
0.15
EV Over EBITDA
2.33
EV to Operating CashFlow
1.86
EV to FreeCashFlow
2.08
Earnings Yield
0.15
FreeCashFlow Yield
0.27
Market Cap
0,20 Bil.
Enterprise Value
0,11 Bil.
Graham Number
33.65
Graham NetNet
8.69

Income Statement Metrics

Net Income per Share
2.68
Income Quality
2.07
ROE
0.14
Return On Assets
0.1
Return On Capital Employed
0.16
Net Income per EBT
0.79
EBT Per Ebit
1.09
Ebit per Revenue
0.04
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.17
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.74
Operating Profit Margin
0.04
Pretax Profit Margin
0.05
Net Profit Margin
0.04

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
1.25
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
5.56
Free CashFlow per Share
4.97
Capex to Operating CashFlow
0.11
Capex to Revenue
0.01
Capex to Depreciation
0.45
Return on Invested Capital
0.12
Return on Tangible Assets
0.1
Days Sales Outstanding
0
Days Payables Outstanding
125.75
Days of Inventory on Hand
72.02
Receivables Turnover
770181000
Payables Turnover
2.9
Inventory Turnover
5.07
Capex per Share
0.59

Balance Sheet

Cash per Share
14,95
Book Value per Share
18,77
Tangible Book Value per Share
18.77
Shareholders Equity per Share
18.77
Interest Debt per Share
1.95
Debt to Equity
0.09
Debt to Assets
0.07
Net Debt to EBITDA
-1.84
Current Ratio
2.98
Tangible Asset Value
0,21 Bil.
Net Current Asset Value
0,14 Bil.
Invested Capital
202474000
Working Capital
0,15 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,07 Bil.
Average Inventory
42938000
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Medifast, Inc. Dividends
Year Dividends Growth
2015 0
2016 1 100%
2017 1 0%
2018 2 50%
2019 3 33.33%
2020 5 25%
2021 6 20%
2022 7 16.67%
2023 5 -50%

Medifast, Inc. Profile

About Medifast, Inc.

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.

CEO
Mr. Daniel R. Chard
Employee
634
Address
100 International Drive
Baltimore, 21202

Medifast, Inc. Executives & BODs

Medifast, Inc. Executives & BODs
# Name Age
1 Mr. Anthony E. Tyree
Chief Business Operations Officer
70
2 Mr. Jonathan Barrett MacKenzie
Vice President of Finance & Chief Accounting Officer
70
3 Ms. Claudia C. Greninger
Chief Human Resources Officer
70
4 Mr. Jason L. Groves Esq.
Executive Vice President, General Counsel & Corporate Secretary
70
5 Mr. Daniel R. Chard
Executive Chairman & Chief Executive Officer
70
6 Mr. James P. Maloney CPA
Chief Financial Officer
70
7 Mr. Nicholas M. Johnson
Chief Field Operations Officer
70
8 Mr. Steven Zenker
Vice President of Investor Relations
70

Medifast, Inc. Competitors